Tim Garnett is a pharmaceutical executive and former Chief Medical Officer at Eli Lilly and Company. With over 30 years of experience, he has led global clinical development, medical affairs, regulatory, and drug safety functions. Garnett has overseen the development and approval of therapies in women’s healthcare, endocrinology, and neuroscience across major markets, including the US, Europe, China, and Japan. He was a board member of Carmot before its acquisition by Roche and has been a longtime advocate for drug safety and LGBT leadership in the Life Sciences industry. Currently, Garnett serves as the Chairman of Ophirex, and is a board member of Maplight.